Morgan Stanley on Biogen (BIIB) Acquisition of Hi-Bio
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $216.03 +6.97%
Rating Summary:
26 Buy, 17 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 20 | New: 25
Rating Summary:
26 Buy, 17 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 20 | New: 25
Join SI Premium – FREE
Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating and $331.00 price target on Biogen (NASDAQ: BIIB)
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $227.69 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Starts TIME dotCom Berhad (TDC:MK) at Overweight
- Goldman Sachs Reiterates Buy Rating on NetEase.com (NTES)
- Freedom Broker Starts AngloGold Ashanti (AU) at Buy
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
